MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference
March 07 2023 - 5:00PM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products and devices for patients with endocrine and
orphan lung diseases, announced today that its Chief Executive
Officer, Michael Castagna, PharmD, will participate in a virtual
presentation at the Oppenheimer 33rd Annual Healthcare Conference
on Tuesday, March 14, 2023 at 2:00 pm (ET).
Interested parties can access a link to the webcast from the
News & Events section of the Company’s website at Events &
Presentations. The webcast replay will remain available for 14 days
following the live presentation.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development
and commercialization of innovative therapeutic products and
devices to address serious unmet medical needs for those living
with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and
device engineering prowess to lessen the burden of diseases such as
diabetes, pulmonary arterial hypertension (PAH) and nontuberculous
mycobacterial (NTM) lung disease. Our signature technologies –
dry-powder formulations and inhalation devices – offer rapid and
convenient delivery of medicines to the deep lung where they can
exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide,
we are on a mission to give people control of their health and the
freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on
LinkedIn, Facebook, Twitter or Instagram.
MannKind Contact:Rose Alinaya,
Investor Relations(818) 661-5000Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024